Gilead Sciences (FRA:GIS) Moat Score: 7/10 (As of Jul. 07, 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
69 GF Score
Price €112.82
GF Value €84.05
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Moat Score?

Gilead Sciences FRA:GIS -1.79% 69 Moat Score is 7 as of Jul. 07, 2026. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €84.05 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Gilead Sciences ranks better than 98.64% on this metric.

Gilead Sciences has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Gilead Sciences has Wide Moat: Gilead Sciences possesses a wide moat due to its valuable intellectual property and patents, particularly in antiviral drugs. The company has strong pricing power and significant R&D capabilities, which support its market leadership and sustainable market share in the pharmaceutical industry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Gilead Sciences might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Gilead Sciences  (FRA:GIS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Gilead Sciences Moat Score Related Terms

FRA:GIS vs PFE, AMGN, BMY: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Moat Score falls into.


FRA:GIS
69GF Score
Gilead Sciences Inc FRA:GIS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Gilead Sciences (FRA:GIS) has a Moat Score of 7 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Gilead Sciences ranks #14 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Gilead Sciences' Moat Score too high?
Gilead Sciences' current Moat Score is 7. Based on the distribution chart, Gilead Sciences ranks #14 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Moat Score compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #14 out of 1032 companies for Moat Score. This places Gilead Sciences in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Gilead Sciences's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €84.05, compared to a current price of €112.82 — trading 34.2% above its estimated fair value. The current Moat Score is 7. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Moat Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €112.82 is trading 34.2% above its estimated GF Value™ of €84.05. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Moat Score: 7
  • GF Value™: €84.05 vs. price of €112.82 (34.2% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for FRA:GIS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€112.82
Price
€84.05
GF Value